Pharmaceutical Business Investment Opportunities

- Our company developing and market potential pharmaceutical medicines that have no side effects. - The business has invested heavily in the research and development of anti-viral drugs. - Today, we have finished R&D and are ready to start production of a new drug that can help to prevent and treat many diseases including COVID-19. - The investment will be utilized to commence production and fulfil purchase orders from around the world.

- We plan to cultivate cannabis for medical purpose. We are yet to register our company. - Soon the company will have the ability to vegetate up to 1,500 plants and flowers concurrently. - We will grow up to 4 different strains of marijuana and will be able to grow from seedling to finished product. - We will dry and process all cannabis into labelled/inventoried vacuum-sealed bags before delivery. - The company will distribute products through wholesale transactions to qualified, licensed marijuana establishments. - From a total investment of $250 thousand, company is expected to generate nearly $660 thousand in gross revenues with a pre-tax income of nearly $1.5 million in year 3, its first full year of operations. - Revenue is expected to grow to nearly $3 million in year 4 and $5.9 million in year 5. - Promoter is based in the Philippines and the business will be operational in Thailand. - Image uploaded in the profile is a stock photo.

Updates on the business: The facility will have growing/extraction/distillation/packaging and R&D lab facilities in order to follow the entire stage of production from mother plants to crystallized forms of stand-alone cannabinoids. The intended R&D lab will be almost 200 sq. m. and will allow us to study lesser-known cannabinoids, and after the start of construction, we are going to sign the 'Partnership Joint Research' program with Athens University. Currently have signed a partnership agreement with a running pharmaceutical company on product supply + joint research program. Later on, we will focus on the distribution channels in each country of presence in order to be prepared to scale to the B2C market with potential own generic medicine and potentially edibles, but that will be decided by the market needs and legislation. We have received an installation license for such end products and as the project progresses we will add new products to the list: - Dried hemp flower > 0.2% THC in the form of teabag (tea bag) for oral consumption; - Hemp oil in drops for oral consumption > 0.2% THC; - Hemp oil for sublingual oral consumption (spray) > 0.2% THC; - Soft cannabis capsules for oral consumption > 0.2% THC; - Capsules with dried hemp blossom > 0.2% THC in powder form for oral consumption. At the moment we have: License and permits; Architectural and engineering plans; Purchase offers from equipment suppliers; All described production processes and laboratories; Long-term land lease for 30+ years with first an option of first to purchase it; Long-term lease and right of build on the neighboring land for the second stage of construction; The entire legal structure of the holding; Verification of processes and architectural solutions under EU GACP & EU GMP standards. By the end of last year have applied for the state subsidy of EUR 3.5mil and have the option to apply for the second state subsidy next year. Additionally, the project has a right for setting fixed corporate tax for the next 12 years. Overall the production facility is projected to grow 6.5+ tons of dried biomaterial (running at 70% capacity) on a single-tier growing table with the ability of scale and potential purchase of third-party biomaterial certified by GACP standards. The EU GMP Laboratory is projected to produce 2+ tons of fine oil with an option of scaling by putting a second processing line. Additionally, the project is built in mind with an option for a second-stage expansion through the building of an additional production site on the neighboring land.